Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?

Curr Oncol. 2022 Dec 12;29(12):9767-9787. doi: 10.3390/curroncol29120768.

Abstract

Radiation therapy represents, together with surgery and systemic treatment, the triad on which the current management of patients with breast cancer is based, achieving high control and survival rates. In recent years we have witnessed a (r)evolution in the conception of breast cancer treatment. The classic scheme of surgery followed by systemic treatment and radiotherapy is being subverted and it is becoming more and more frequent to propose the primary administration of systemic treatment before surgery, seeking to maximize its effect and favoring not only the performance of more conservative surgeries but also, in selected cases, increasing the rates of disease-free survival and overall survival. Radiotherapy is also evolving toward a change in perspective: considering preoperative primary administration of radiotherapy may be useful in selected groups. Advances in radiobiological knowledge, together with technological improvements that are constantly being incorporated into clinical practice, support the administration of increasingly reliable, precise, and effective radiotherapy, as well as its safe combination with antitumor drugs or immunotherapy in the primary preoperative context. In this paper, we present a narrative review of the usefulness of preoperative radiotherapy for breast cancer patients and the possibilities for its combination with other therapies.

Keywords: breast cancer; neoadjuvant radiochemotherapy; preoperative radiotherapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Neoadjuvant Therapy

Substances

  • Antineoplastic Agents

Grants and funding

This research received no external funding.